Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial

Critical Care Medicine

Volumn 27, Issue 11, 1999, Pages 2346-2350

  Corwin, Howard L ^a   Gettinger, Andrew ^a   Rodriguez, Robert M ^b   Pearl, Ronald G ^b   Gubler, K Dean ^c   Enny, Christopher ^d   Colton, Theodore ^e   Corwin, Michael J ^e  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

^e BOSTON UNIVERSITY   (United States)

Author keywords

Anemia; Blood substitutes; Blood transfusion; Critical care; Erythropoietin; Intensive care unit; Transfusion medicine

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOCRIT; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; REVIEW; THROMBOCYTOPENIA; THROMBOCYTOSIS;

EID: 0032760409     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199911000-00004     Document Type: Review

References (16)

1. 1. Corwin HC, Parsonnet KC, Gettinger A: RBC transfusion in the ICU: Is there a reason? Chest 1995; 108:767-771
2. 2. Groeger JS, Guntupalli KK, Strosberg M, et al: Descriptive analysis of critical care units in the United States: Patient characteristics and intensive care unit utilization. Crit Care Med 1993; 21:279-291
3. 3. Krafte-Jacobs B, Levetown ML, Bray GL, et al: Erythropoietin response to critical illness. Crit Care Med 1994; 22:821-826
4. 4. Rogiers P, Zhang H, Leeman M, et al: Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23: 159-162
5. 5. Gabriel A, Kozek S, Chiari A, et al: High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998; 44:361-367
6. 6. Wilcox R: Kolmogorov-Smirnov test. In: Enclycopedia of Biostatistics. Vol 3. Armitage P, Colton T (Eds). Chichester, John Wiley & Sons, 1998, pp 2174-2176
7. 7. Littenberg B, Corwin HC, Gettinger A, et al: A practice guideline and decision aide for blood transfusion. Immunohematology 1995; 11:88-94
8. 8. Cazzola M, Mercuriali F, Brugnara C: Use of recombinant erythropoeitin outside the setting of uremia. Blood 1997; 89: 4248-4267
9. 9. Still JM, Belcher K, Law EJ, et al: A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995; 38: 233-236
10. 10. Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269:3024-3029
11. 11. Fitzgerald RD, Martin CM, Dietz GE, et al: Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit Care Med 1997; 25:726-732
12. 12. Sowade O, Gross J, Sowade B, et al: Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta. J Lab Clin Med 1997; 129:97-105
13. 13. Goldberg MA, McCutchen JW, Jove M, et al: A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25:544-552
14. 14. Nucci ML, Abuchowski A: The search for blood substitutes. Sci Am 1998; 278:72-79
15. 15. Mohandas K, Aledort L: Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995; 35:427-430
16. 16. Cantor SB, Hudson DV, Lichtiger B, et al: Costs of blood transfusion: A process flow analysis. J Clin Oncol 1998; 16:2364-2370